Juan Martin-Liberal
Overview
Explore the profile of Juan Martin-Liberal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
883
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martin-Liberal J, Joerger M, et al.
Nature
. 2025 Feb;
639(8054):E18.
PMID: 40000750
No abstract available.
2.
Eigentler T, Thomas I, Samoylenko I, Erdmann M, Heinzerling L, Ochsenreither S, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39904560
Background: CV8102, a toll-like receptor 7/8 and RIG I agonist, has demonstrated antitumor immune responses in preclinical studies. We investigated intratumoral (IT) administration of CV8102 in patients with anti-programmed cell...
3.
Martin-Liberal J, Marquez-Rodas I, Cerezuela-Fuentes P, Soria A, Garicano F, Medina J, et al.
Cancer Treat Rev
. 2025 Jan;
133:102886.
PMID: 39879863
The global incidence of metastatic melanoma with BRAF mutations, characterized by aggressive behavior and poor prognosis, is rising. Recent treatment advances, including immune checkpoint inhibitors (ICI) and targeted therapies (TT)...
4.
Martinez-Recio S, Molina-Perez M, Munoz-Couselo E, Sevillano-Tripero A, Aya F, Arance A, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796770
Background: Anti-PD-1-based immunotherapy has improved outcomes in stage IIB to IV resected melanoma patients in clinical trials. However, little is known about real-world outcomes, prognostic factors and patterns of relapse....
5.
Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martin-Liberal J, Joerger M, et al.
Nature
. 2024 Dec;
637(8048):1218-1227.
PMID: 39663448
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment. Yet, response rates are still limited, and tumour progression...
6.
Martin-Liberal J, Garralda E, Garcia-Donas J, Soto-Castillo J, Mussetti A, Codony C, et al.
Future Oncol
. 2024 Aug;
20(32):2437-2445.
PMID: 39129675
The SWI/SNF complex is a chromatin remodeling complex comprised by several proteins such as SMARCA4 or SMARCB1. Mutations in its components can lead to the development of aggressive rhabdoid tumors...
7.
Lopez-Cerda M, Lorenzo-Sanz L, da Silva-Diz V, Llop S, Penin R, Bermejo J, et al.
J Exp Clin Cancer Res
. 2024 Jul;
43(1):211.
PMID: 39075581
Background: Early cutaneous squamous cell carcinomas (cSCCs) generally show epithelial differentiation features and good prognosis, whereas advanced cSCCs present mesenchymal traits associated with tumor relapse, metastasis, and poor survival. Currently,...
8.
Cerezuela-Fuentes P, Gonzalez-Cao M, Puertolas T, Luis Manzano J, Maldonado C, Yelamos O, et al.
Clin Transl Oncol
. 2024 Jul;
27(1):386-391.
PMID: 38951438
Background: Novel and highly effective drugs for non-melanoma skin cancer (NMSC) improve patient outcomes, but their high cost strains healthcare systems. Spain's decentralized public health system, managed by 17 autonomous...
9.
Marquez-Rodas I, Alvarez A, Arance A, Valduvieco I, Berciano-Guerrero M, Delgado R, et al.
Neuro Oncol
. 2024 Jul;
26(11):2074-2083.
PMID: 38946469
Background: Encorafenib plus binimetinib (EB) is a standard-of-care treatment for advanced BRAFV600-mutant melanoma. We assessed the efficacy and safety of encorafenib plus binimetinib in patients with BRAFV600-mutant melanoma and brain...
10.
Lorenzo-Sanz L, Lopez-Cerda M, da Silva-Diz V, Artes M, Llop S, Penin R, et al.
Nat Commun
. 2024 Jun;
15(1):5352.
PMID: 38914547
Immune checkpoint blockade (ICB) approaches have changed the therapeutic landscape for many tumor types. However, half of cutaneous squamous cell carcinoma (cSCC) patients remain unresponsive or develop resistance. Here, we...